<DOC>
	<DOC>NCT02117050</DOC>
	<brief_summary>This is a Phase IV, prospective, open-label, multi-center trial to assess the treatment satisfaction in patients with relapsing forms of Multiple Sclerosis (MS) who are currently being treated with, but are considering discontinuing treatment with Tecfidera™.</brief_summary>
	<brief_title>RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<mesh_term>Dimethyl Fumarate</mesh_term>
	<criteria>Key inclusion Criteria: Diagnosis of relapsing form of MS Have declared a desire/plan to discontinue treatment with Tecfidera due to tolerability issues and/or lack of efficacy Expanded Disability Status Scale (EDSS) score 0 to 5.0 inclusive Other protocol defined inclusion criteria could apply Key exclusion Criteria: Pregnant or lactating Significant renal or hepatic impairment or other significant disease that would compromise adherence and completion of the trial Other protocol defined exclusion criteria could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Rebif ®</keyword>
	<keyword>Tecfidera ™</keyword>
	<keyword>treatment change</keyword>
</DOC>